Full text

Turn on search term navigation

© 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:  https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Purpose

Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. While treatable, there is substantial interindividual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate or aggressive disease course is very limited. There is, therefore, a need for integrated predictive tools to inform individualised treatment decision making.

Participants

Established with the aim of addressing this need for individualised predictive tools, FutureMS is a nationally representative, prospective observational cohort study of 440 adults with a new diagnosis of relapsing-remitting MS living in Scotland at the time of diagnosis between May 2016 and March 2019.

Findings to date

The study aims to explore the pathobiology and determinants of disease heterogeneity in MS and combines detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow-up at year 1 is complete. Here, we describe the cohort design and present a profile of the participants at baseline and 1 year of follow-up.

Future plans

A third follow-up wave for the cohort has recently begun at 5 years after first visit and a further wave of follow-up is funded for year 10. Longer-term follow-up is anticipated thereafter.

Details

Title
FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
Author
Kearns, Patrick K A 1   VIAFID ORCID Logo  ; Martin, Sarah J 2 ; Chang, Jessie 3 ; Meijboom, Rozanna 4   VIAFID ORCID Logo  ; York, Elizabeth N 4   VIAFID ORCID Logo  ; Chen, Yingdi 5   VIAFID ORCID Logo  ; Weaver, Christine 3 ; Stenson, Amy 3 ; Hafezi, Katarzyna 6 ; Thomson, Stacey 7 ; Freyer, Elizabeth 7 ; Murphy, Lee 6 ; Harroud, Adil 8 ; Foley, Peter 3 ; Hunt, David 3 ; McLeod, Margaret 9 ; O'Riordan, Jonathon 10 ; Carod-Artal, F J 11 ; MacDougall, Niall J J 12   VIAFID ORCID Logo  ; Baranzini, Sergio E 8 ; Waldman, Adam D 4 ; Connick, Peter 4   VIAFID ORCID Logo  ; Siddharthan Chandran 3   VIAFID ORCID Logo 

 Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK; Chromatin Lab, Genome Regulation Section, The University of Edinburgh MRC Human Genetics Unit, Edinburgh, UK; Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh, UK; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; Department of Neurology, Institute of Clinical Neurosciences, NHS Greater Glasgow and Clyde, Glasgow, UK; Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK 
 Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; Department of Neurology, Institute of Clinical Neurosciences, NHS Greater Glasgow and Clyde, Glasgow, UK 
 Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK; Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK 
 Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK 
 Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK 
 Wellcome Trust Clinical Research Facility, Edinburgh, UK 
 Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK 
 Department of Neurology, Weill Institute of Clinical Neuroscience, San Francisco, California, USA 
 Department of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK 
10  Tayside Centre for Clinical Neurosciences, University of Dundee Division of Neuroscience, Dundee, UK 
11  Department of Neurology, Raigmore Hospital, Inverness, UK 
12  Anne Rowling Regenerative Neurology Clinic, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK; Department of Neurology, Wishaw General Hospital, Wishaw, UK 
First page
e058506
Section
Neurology
Publication year
2022
Publication date
2022
Publisher
BMJ Publishing Group LTD
e-ISSN
20446055
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2724921289
Copyright
© 2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:  https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.